Apoquel is the drug in the cupboard with a moving target on it. Almost every other medication your dog takes has one schedule that never changes. Apoquel starts at twice daily, runs that way for two weeks, and then — on a day nobody circles on a calendar — quietly becomes a once-a-day drug for the rest of your dog's life.
So the question in the title has two opposite answers, and which one applies to you depends on a date. Search it at 10pm and you get forum threads insisting a double dose is nothing, alongside vet-page boilerplate saying never give two at once. Both are quoting something real. Neither asks which day you are on, which is the only thing that decides.
Key takeaways
- The calendar decides, not the tablet. The label doses Apoquel "twice daily for up to 14 days, and then administered once daily for maintenance therapy" — so two doses is either the regimen or an overdose depending on the date.¹
- One accidental double is a long way from the numbers that matter. A doubled dose is about 0.8–1.2 mg/kg; poison-control guidance puts signs at 10–15 mg/kg and acute kidney injury at 12–38 mg/kg.⁵
- The breakthrough itch you are seeing is real and measured. In the pivotal trial, itch scores were 66.7% improved at day 14 on twice-daily dosing and 47.4% at day 28 on once-daily.⁷ That is a vet conversation, not a reason to self-double.
- The bottle is the real emergency. The chewable is flavoured, 91.6% of doses are taken voluntarily within five minutes, and it ships in bottles of up to 250.²⁶
Can I give my dog two doses of Apoquel?
It depends which day you are on, and that is not a hedge — it is written into the label. Apoquel is dosed at "0.18 to 0.27 mg oclacitinib/lb (0.4 to 0.6 mg oclacitinib/kg) body weight, administered orally, twice daily for up to 14 days, and then administered once daily for maintenance therapy."¹ The Merck Veterinary Manual states the same schedule in shorthand: "0.4–0.6 mg/kg, PO, q 12 h for 2 wk, then q 24 h."⁴
So if your dog started Apoquel eight days ago and has had two tablets today, that is the prescribed course working exactly as intended. If your dog has been on it for eight months and has had two tablets today, that is an extra dose, and VCA's owner-facing instruction applies: "Do not give the pet two doses at once."³
Either way, if a dose has gone in that you did not intend, VCA's instruction for that moment is: "If you suspect an overdose or an adverse reaction to the medication, call your veterinary office immediately."³ Which of these you are in changes the answer more than anything else on this page.
| Which situation are you in? | What it means | What to do |
|---|---|---|
| Your dog is in the first 14 days and has had two tablets today | This is the labelled regimen, not an overdose¹ | Nothing is wrong. Confirm the start date so you know when the step-down to once daily is due |
| Two tablets given the same day by two people, dog on once-daily maintenance | The commonest version, at roughly 0.8–1.2 mg/kg against a 10 mg/kg concern level⁵ | Call your clinic today. Skipping tomorrow's dose is their call, not yours |
| You have been giving two a day on purpose because one wasn't holding | Not a single incident — this is the exposure pattern the label's safety studies flag¹ | Tell your vet how long it has been going on. There are other options; this is the conversation to have |
| Your dog got into the bottle or blister pack | Potentially 10–38 mg/kg territory, where kidney and liver injury are reported⁵ | Emergency. Clinic or ASPCA APCC (888) 426-4435 now⁹ |
| A cat ate your dog's Apoquel | Off-label species; poison-control guidance is that cats "may be especially vulnerable"⁵ | Emergency — call now, with the tablet strength and a count if you have one |
| A tablet meant for a much heavier dog, given to a small one | An arithmetic problem rather than a counting one — three strengths share one bottle shape¹ | Call with both weights and the tablet strength in milligrams |
From the FDA-approved Apoquel label, VCA Animal Hospitals' oclacitinib handout, and ASPCA Animal Poison Control Center guidance. The rows differ in how fast you dial, not whether.
What should you do in the first hour?
Work out which row you are in, then call with four facts ready. Do not try to make your dog vomit on your own initiative — whether decontamination is worth doing depends on a dose figure you are about to help them calculate.
- Your dog's current weight. Every threshold in this drug's literature is per kilogram, so a doubled tablet in a 40 kg dog is a different exposure entirely from the same tablet in a 5 kg one.
- The tablet strength, and how many. Apoquel comes as 3.6 mg, 5.4 mg and 16 mg tablets, all scored, all white and oval, and prescriptions frequently call for half of one.¹ "Two tablets" means little without the milligrams.
- What day of treatment your dog is on. The one nobody has ready, and the one that changes the answer most.
- Whether it was the film-coated tablet or the chewable, and whether it came from your hand or from the bottle — two different incidents with two different worst cases.
If you cannot reach a clinic, the ASPCA Animal Poison Control Center takes calls on (888) 426-4435, 24 hours a day, 365 days a year; a consultation fee may apply.⁹ One thing worth raising if it applies: the label states Apoquel "is not for use in dogs with serious infections" and "may increase susceptibility to infection, including demodicosis, and exacerbation of neoplastic conditions."¹ If your dog has an active skin infection or a mass under treatment, say so.
How much oclacitinib is actually in a doubled dose?
About 0.8 to 1.2 milligrams per kilogram — double the labelled 0.4 to 0.6 — and that is a long way below any figure associated with harm. The useful comparison comes from the ASPCA Animal Poison Control Center, which has been tracking oclacitinib exposures since the chewable formulation arrived: "GI and systemic signs have occurred at dosages of 10–15 mg/kg, with acute kidney injury reported at 12–38 mg/kg."⁵ Published guidance drawn from those cases sets "the level of concern for decontamination for young healthy animals" at 10 mg/kg, for dogs and cats alike.⁶ The Merck Veterinary Manual notes the same class of outcome from the other direction: "Acute kidney injury possible with toxic doses (eg, 27.3 mg/kg)."⁴
Put those beside each other and the gap is roughly tenfold. As accidental doublings go this is one of the more forgiving ones — nothing like a doubled insulin dose or a doubled NSAID — and the reassurance you have been reading online is, for once, pointing the right way. It just never arrives with the numbers attached.
One caveat belongs with that chart. The 5X bar is not the "5X was proven safe" line the forums repeat — it is the label's margin-of-safety group, and what it actually establishes is about a schedule rather than a dose.
Why does the label allow twice daily for 14 days and not after?
Because the drug's own safety studies found that sustained twice-daily dosing is where the immune-system effects show up, and those effects are cumulative rather than acute. Apoquel is a Janus kinase inhibitor, and the label does not hedge about what that means: "APOQUEL modulates the immune system."¹
In the margin-of-safety study, one-year-old Beagles received oclacitinib "twice daily for 6 weeks, followed by once daily for 20 weeks" at 1X, 3X and 5X the maximum exposure dose. Findings considered drug-related included papillomas and "a dose-dependent increase in the number and frequency of interdigital furunculosis (cysts)"; microscopically, "decreased cellularity (lymphoid) in Gut-Associated Lymphoid Tissue (GALT), spleen, thymus, cervical and mesenteric lymph node; and decreased cellularity of sternal and femoral bone marrow." Five treated dogs had "microscopic evidence of mild interstitial pneumonia."¹ The blood-count changes carry their own timestamp: a "mild, dose-dependent reduction in hemoglobin, hematocrit, and reticulocyte counts during the twice daily dosing period."¹
The study nobody quotes is the more pointed one. A parallel margin-of-safety study in six-month-old dogs, dosed twice daily "for the entire study" rather than stepping down, "was discontinued after four months due to the development of bacterial pneumonia and generalized demodex mange infections in dogs in the high dose (3X and 5X) treatment groups."¹ A trial stopped early for infections is the clearest statement the label makes about what sustained elevated dosing does.
None of which means Apoquel is dangerous. Long-term data at the labelled regimen is reassuring: 247 dogs took it for up to 630 days, and "haematology and serum chemistry means remained within the normal reference ranges."⁸ The useful reading is narrower — the risk in this drug attaches to the schedule, not to any single tablet. One extra dose is one event on a drug with a 4.1-hour plasma half-life; it is gone by tomorrow.¹ Six weeks of twice-daily dosing is the exposure those studies describe.
The itch comes back before the next dose — isn't that a reason to double?
It is a real observation, and the single most common route by which this drug gets doubled on purpose. But the fix is a conversation with your vet rather than a second tablet, and the reason is worth understanding.
First, you are not imagining it. In the pivotal double-masked trial of 299 client-owned dogs, owner-assessed itch scores improved from baseline by 29.5% on day 1, 42.3% on day 2, 61.5% on day 7 and 66.7% on day 14 — then measured 47.4% on day 28.⁷ Day 14 is the last day of twice-daily dosing; day 28 is a fortnight into once-daily maintenance. The best itch control in the study happened on the twice-daily regimen, and roughly 19 percentage points of it were given back after the step-down.
The pharmacology says why. Oclacitinib peaks in "less than 1 hour" and has a terminal half-life after oral dosing of 4.1 hours.¹ This is a drug that arrives fast and leaves fast, asked on maintenance to cover a 24-hour interval — and for a proportion of dogs it does not fully manage it.
What that chart does not license is a decision to keep dosing twice daily. The previous section is the reason: that is precisely the exposure pattern the safety studies flag, and it is why the label caps the twice-daily phase at 14 days.¹ Practically, the option your vet has and you do not is to add something alongside it rather than increase it — and there are real options, since oclacitinib is neither the only nor always the best tool for the job. The label is blunt about what it is not: "Oclacitinib is not a corticosteroid or an antihistamine."¹ If you have been reaching for an over-the-counter antihistamine like Benadryl to bridge the gap, that is also worth raising, because it is a different drug class doing a different job.
Is the chewable a different problem from the tablet?
Yes, and currently the more urgent one. Apoquel Chewable is flavoured, and the palatability data is the point: in a controlled US field study of 1,662 doses given to 120 dogs, "a total of 1,522 doses (91.6%) were accepted voluntarily within 5 minutes."² A tablet a dog spits out cannot be over-consumed. A chewable taken like a treat nine times out of ten is something else.
That change has produced a measurable signal. Veterinary guidance published in the Canadian Veterinary Journal reports that searches on "oclacitinib toxicity" and similar terms in 2024 ran "460% higher" than in 2022, and names the mechanism plainly: the product is palatable, flavoured with pork liver and brewer's yeast, and "when a medication is packaged into 100-count blister packs or bottles, or 250-count bottles in the US, pets can access a large number of chewables."⁶
The arithmetic separates the two incidents cleanly. A doubled tablet is about 1 mg/kg. A 10 kg dog that gets through twenty 16 mg chewables has taken 320 mg — 32 mg/kg, squarely inside the 12–38 mg/kg range in which acute kidney injury has been reported.⁵ In severe cases, marked elevations in BUN and creatinine appeared "within 12 to 72 h after ingestion," which is why a dog that seems fine at bedtime is not yet evidence of anything.⁶
Cats deserve their own sentence. Apoquel is labelled "for oral use in dogs only," poison-control guidance is that cats "may be especially vulnerable,"⁵ and the flavouring cuts across species — hence the published advice to "consider non-chewable oclacitinib tablets in households with cats" and to store the chewables "in a locked cabinet."⁶
What should you watch for, and for how long?
For a single doubled dose, tonight and tomorrow — and most likely you will see nothing. In the pivotal field study, reactions over days 0–16 were diarrhoea (4.6% on Apoquel against 3.4% on placebo), vomiting (3.9% against 4.1%), anorexia (2.6% against 0%), a new cutaneous or subcutaneous lump (2.6% against 2.7%) and lethargy (2.0% against 1.4%).¹ Those are normal-dose figures, and several barely separate from placebo.
| What you're seeing | What it may point at | Urgency |
|---|---|---|
| Nothing at all, hours later | The commonest outcome after a single doubled dose¹ | Still call the same day to agree what tomorrow's dose should be |
| One episode of vomiting, loose stool, or an off appetite¹ | The listed reactions, at rates close to placebo in the field study¹ | Call today; mention it, and keep water available |
| Unusual tiredness that settles by the next day¹ | Lethargy is on both the field-study and post-approval lists¹ | Call today. If it deepens rather than lifts, call again |
| A new skin lump, a spreading skin infection, or a fever³ | The immune-modulation signals VCA tells owners to report — relevant to sustained over-dosing, not one tablet³ | Book an appointment, and say how long the dosing has been doubled |
| Drinking or urinating far more than usual, or not eating for a day⁵ | Possible kidney involvement, reported after large ingestions at 12–38 mg/kg⁵ | Emergency — go in now, especially after a bottle raid |
| Collapse, weakness, a racing or irregular heartbeat, or a seizure⁵ | Hypotension, arrhythmias and dull mentation appear in poison-control reports; seizures are on the label's post-approval list¹⁵ | Emergency — go in now |
Signs as listed in the FDA-approved Apoquel label, VCA Animal Hospitals' oclacitinib handout, and ASPCA Animal Poison Control Center guidance. This is a guide to urgency, not a diagnosis — describe what you are seeing to a veterinarian rather than matching it to a row yourself.
The bottom two rows are genuinely unlikely after one extra tablet from your hand. They belong to the bottle-raid version of this incident, and they are here so that you recognise them at 2am rather than talk yourself out of them.
How do you stop this happening again?
By writing down the two things this drug makes unusually easy to lose: whether today's dose has been given, and which phase of the schedule you are in. Apoquel gets doubled more often than its risk profile deserves, for reasons that are structural rather than careless.
- The schedule changes on day 14, and nothing announces it. Every other drug in the cupboard has one rhythm. This one has two, and the switch falls on a date somebody has to remember.
- It is a small white oval in three strengths. The 3.6 mg, 5.4 mg and 16 mg tablets are all white, oval and scored, told apart by an S, M or L next to "AQ."¹ Half-tablet doses are routine.
- The chewable does not feel like medication. More than nine doses in ten are taken voluntarily within five minutes,² which is what stops handing one over at the back door from registering as "I dosed the dog."
What closes the gap is a record made at the moment of giving — the time, the strength in milligrams, and which day of the course you are on — somewhere both people can see it before they reach for the bottle. And the bottle belongs in a cupboard the dog cannot open, which the label asks for directly.¹
The underlying failure is the one described in why pets miss their medication doses, running in reverse: the missing shared record that causes a skipped dose causes a doubled one. The systems in how to avoid double dosing your pet's medication apply here with one addition — log the phase alongside the dose, because "two today" is only an error on one side of day 14.
Veterinary medical disclaimer: SteadyTails is a logging and coordination tool, not a substitute for veterinary care. Nothing here is a dosing instruction. Apoquel is a prescription immunomodulator, tablet strengths differ, and the right response to an extra or missed dose is specific to your dog and to where you are in the course — only your veterinarian can tell you what to do about it and when the next dose should be given. Never change a dosing frequency on your own. If your dog has received extra Apoquel, has eaten from the bottle, or shows collapse, weakness, an irregular heartbeat, a seizure, or a marked change in drinking or urination, contact your veterinarian or an emergency animal hospital immediately. The ASPCA Animal Poison Control Center is available on (888) 426-4435, 24 hours a day, 365 days a year; a consultation fee may apply.⁹
The dose that changes halfway through is the one that gets doubled
Twice a day for two weeks, then once a day forever — with two people, one bottle and no shared record, that is a schedule built to go wrong. SteadyTails records every dose with a name, a timestamp and the amount given, on a timeline the whole household can see, and clears the reminder on everyone's phone the moment somebody logs it. Coming soon to iOS and Android.
Join the SteadyTails waitlist →References
- APOQUEL (oclacitinib maleate) tablet, coated — FDA-approved prescribing information, Zoetis Inc., via DailyMed (US National Library of Medicine), NADA 141-345. Description: "APOQUEL (oclacitinib maleate) is a synthetic Janus Kinase (JAK) inhibitor... For oral use in dogs only." Indications: "Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age." Dosage: "The dose of APOQUEL (oclacitinib maleate) tablets is 0.18 to 0.27 mg oclacitinib/lb (0.4 to 0.6 mg oclacitinib/kg) body weight, administered orally, twice daily for up to 14 days, and then administered once daily for maintenance therapy." Warnings: "APOQUEL modulates the immune system"; "APOQUEL is not for use in dogs with serious infections"; "APOQUEL may increase susceptibility to infection, including demodicosis, and exacerbation of neoplastic conditions"; "Keep APOQUEL in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose." Adverse reactions, days 0-16 of the masked atopic dermatitis field study: diarrhea (4.6% APOQUEL, 3.4% placebo), vomiting (3.9% APOQUEL, 4.1% placebo), anorexia (2.6% APOQUEL, 0% placebo), new cutaneous or subcutaneous lump (2.6% APOQUEL, 2.7% placebo), lethargy (2.0% APOQUEL, 1.4% placebo); "In most cases, diarrhea, vomiting, anorexia, and lethargy spontaneously resolved with continued dosing." Post-Approval Experience (2020), in decreasing order of reporting frequency: "Vomiting, lethargy, anorexia, diarrhea, elevated liver enzymes, dermatitis (i.e. crusts, pododermatitis, pyoderma), seizures, polydipsia, and demodicosis." Mechanism: "Oclacitinib is not a corticosteroid or an antihistamine." Pharmacokinetics: "mean time to peak plasma concentrations (Tmax) of less than 1 hour"; "Following IV and PO administration, the terminal t1/2 appeared similar with mean values of 3.5 (2.2, 4.7) and 4.1 (3.1, 5.2) hours, respectively." Animal Safety, Margin of Safety in 12 Month Old Dogs: "Oclacitinib maleate was administered to healthy, one-year-old Beagle dogs twice daily for 6 weeks, followed by once daily for 20 weeks, at 0.6 mg/kg (1X maximum exposure dose, 8 dogs), 1.8 mg/kg (3X, 8 dogs), and 3.0 mg/kg (5X, 8 dogs) oclacitinib for 26 weeks"; findings included "papillomas and a dose-dependent increase in the number and frequency of interdigital furunculosis (cysts)", "decreased cellularity (lymphoid) in Gut-Associated Lymphoid Tissue (GALT), spleen, thymus, cervical and mesenteric lymph node; and decreased cellularity of sternal and femoral bone marrow", "Five oclacitinib maleate-treated dogs had microscopic evidence of mild interstitial pneumonia", and "mild, dose-dependent reduction in hemoglobin, hematocrit, and reticulocyte counts during the twice daily dosing period." Margin of Safety in 6 Month Old Dogs: "A margin of safety study in 6-month-old dogs was discontinued after four months due to the development of bacterial pneumonia and generalized demodex mange infections in dogs in the high dose (3X and 5X) treatment groups, dosed at 1.8 and 3.0 mg/kg oclacitinib twice daily, for the entire study." How Supplied: "APOQUEL tablets contain 3.6 mg, 5.4 mg, or 16 mg of oclacitinib as oclacitinib maleate per tablet... Each tablet is scored and marked with AQ and either an S, M, or L." dailymed.nlm.nih.gov Retrieved 2026-09-01.
- APOQUEL CHEWABLE (oclacitinib chewable tablet) — FDA-approved prescribing information, Zoetis Inc., via DailyMed (US National Library of Medicine). Dosage: "The dose of APOQUEL CHEWABLE (oclacitinib chewable tablet) is 0.18 to 0.27 mg oclacitinib/lb (0.4 to 0.6 mg oclacitinib/kg) body weight, administered orally, twice daily for up to 14 days, and then administered once daily for maintenance therapy." Palatability: "In a well-controlled U.S. field study, in which 1,662 doses of APOQUEL CHEWABLE were administered to 120 dogs, a total of 1,522 doses (91.6%) were accepted voluntarily within 5 minutes. Of the 140 doses unconsumed after 5 minutes, 134 (8%) were consumed with assistance (with food treats or by pilling), and 6 (0.4%) doses were refused." Warnings: "Keep APOQUEL CHEWABLE in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose." dailymed.nlm.nih.gov Retrieved 2026-09-01.
- VCA Animal Hospitals. Oclacitinib — "Oclacitinib (brand name Apoquel) is an oral medication used to manage itching associated with allergic dermatitis (including atopy) in dogs at least 12 months of age"; side effects include "Gastrointestinal effects, such as vomiting, diarrhea, and decreased appetite; Lethargy; Increased susceptibility to infections; New skin growths"; "If you miss a dose, give it as soon as you remember, and then continue with the regular dosing schedule. However, if it is almost time for the next dose, skip the missed dose and resume the regular dosing schedule. Do not give the pet two doses at once"; "If you suspect an overdose or an adverse reaction to the medication, call your veterinary office immediately"; do not use in "Pets with current or recent demodectic mange; Pets with serious infections; Pets with cancer or with a history of cancer; Dogs younger than 12 months old." vcahospitals.com Retrieved 2026-09-01.
- Merck Veterinary Manual. Atopic Dermatitis in Dogs — oclacitinib dosing "0.4–0.6 mg/kg, PO, q 12 h for 2 wk, then q 24 h"; "Fast onset of action (within 24 h) for pruritus control"; "Indicated for acute flares and long-term management of pruritus in dogs 12 mo or older"; "May increase susceptibility to infections, demodicosis, and neoplastic conditions"; "Acute kidney injury possible with toxic doses (eg, 27.3 mg/kg)." merckvetmanual.com Retrieved 2026-09-01.
- ASPCA Animal Poison Control Center / ASPCApro. Research on Oclacitinib Chewable Overdose & Toxicity in Pets — "GI and systemic signs have occurred at dosages of 10–15 mg/kg, with acute kidney injury reported at 12–38 mg/kg"; overdose signs "include not only gastrointestinal distress (vomiting, diarrhea, abdominal pain) but also cardiovascular issues (hypotension, arrhythmias, new murmurs), central nervous system signs (lethargy, dull mentation, elevated third eyelid), acute kidney injury, hepatotoxicity and in some cases, death"; "Cats may be especially vulnerable"; "The chewable tablets should be stored securely to prevent accidental ingestion." aspcapro.org Retrieved 2026-09-01.
- "Do you know how to minimize overdoses of chewable oclacitinib?" Canadian Veterinary Journal 2026 Jan 1;67(1):112–115, via PubMed Central — "the number of searches on 'oclacitinib toxicity' and similar terms... conducted from January 1, 2024 to December 30, 2024 were 460% higher" than 2022; "the product is palatable" and is flavoured with pork liver and brewer's yeast; "when a medication is packaged into 100-count blister packs or bottles, or 250-count bottles in the US, pets can access a large number of chewables"; "For both dogs and cats, the level of concern for decontamination for young healthy animals is 10 mg/kg"; marked elevations in BUN and creatinine occurred "within 12 to 72 h after ingestion"; "cats seem to be more sensitive than dogs"; recommendations: "When making prescribing decisions for oclacitinib, consider non-chewable oclacitinib tablets in households with cats", "consider keeping cats out of the room when the dog is receiving its medication", and "Secure chewable oclacitinib maleate by storing it in a locked cabinet." pmc.ncbi.nlm.nih.gov Retrieved 2026-09-01.
- Cosgrove SB, Wren JA, Cleaver DM, et al. "A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel) in client-owned dogs with atopic dermatitis." Veterinary Dermatology 2013 Dec;24(6):587-97. Methods: "Dogs were randomized to receive either oclacitinib (0.4-0.6 mg/kg twice daily for 14 days and then once daily for up to 112 days) or an excipient-matched placebo"; 299 client-owned dogs at 18 specialty clinics. Results: "On days 1, 2, 7, 14 and 28, oclacitinib-treated dogs had a 29.5, 42.3, 61.5, 66.7 and 47.4% reduction from baseline in owner-assessed pruritus scores, respectively, compared with a 6.5, 9.1, 6.5, 3.9 and 10.4% reduction in placebo-treated dogs." pubmed.ncbi.nlm.nih.gov Retrieved 2026-09-01.
- Cosgrove SB, Cleaver DM, King VL, et al. "Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life." Veterinary Dermatology 2015 Jun;26(3):171-9. Methods: "Dogs received 0.4-0.6 mg/kg oclacitinib twice a day for 14 days, then once a day for up to 630 days"; 247 client-owned dogs at 26 clinics. Results: "The percentage of dogs showing greater than or equal to 50% reduction from baseline on day 90 was 63.9% for pruritus and 66.4% for dermatitis"; "Urinary tract infection/cystitis, vomiting, otitis, pyoderma and diarrhoea were the most frequently reported (>5% of dogs) abnormal clinical signs"; "Haematology and serum chemistry means remained within the normal reference ranges." pubmed.ncbi.nlm.nih.gov Retrieved 2026-09-01.
- ASPCA. Animal Poison Control Center — "(888) 426-4435"; "We are available 24/7, 365 days a year, so you can get expert guidance the moment a poisoning concern arises"; "A consultation fee may apply." aspca.org Retrieved 2026-09-01.